Bausch Health Cos Inc. $BHC Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC trimmed its holdings in shares of Bausch Health Cos Inc. (NYSE:BHC) by 51.8% during the third quarter, Holdings Channel reports. The fund owned 2,963,184 shares of the company’s stock after selling 3,189,802 shares during the quarter. SG Americas Securities LLC’s holdings in Bausch Health Cos were worth $19,113,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Russell Investments Group Ltd. increased its stake in shares of Bausch Health Cos by 65.9% in the second quarter. Russell Investments Group Ltd. now owns 7,819 shares of the company’s stock worth $51,000 after buying an additional 3,106 shares during the last quarter. Alpha Wealth Funds LLC bought a new stake in shares of Bausch Health Cos in the 2nd quarter worth about $65,000. Stratos Wealth Advisors LLC acquired a new stake in shares of Bausch Health Cos in the 2nd quarter valued at about $67,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Bausch Health Cos during the first quarter worth about $68,000. Finally, Norges Bank acquired a new position in shares of Bausch Health Cos in the 2nd quarter worth approximately $117,000. Institutional investors and hedge funds own 78.65% of the company’s stock.

Bausch Health Cos Price Performance

Shares of NYSE:BHC opened at $7.79 on Friday. The firm’s 50 day moving average is $6.83 and its two-hundred day moving average is $6.73. The company has a current ratio of 1.30, a quick ratio of 0.97 and a debt-to-equity ratio of 57.48. The firm has a market capitalization of $2.89 billion, a P/E ratio of 8.03 and a beta of 0.37. Bausch Health Cos Inc. has a 52 week low of $4.25 and a 52 week high of $8.69.

Analysts Set New Price Targets

A number of analysts have weighed in on BHC shares. Barclays began coverage on shares of Bausch Health Cos in a report on Monday, December 8th. They set an “equal weight” rating and a $8.00 target price on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Bausch Health Cos in a report on Monday, December 29th. Truist Financial upped their target price on Bausch Health Cos from $7.00 to $8.00 and gave the company a “hold” rating in a report on Wednesday. Raymond James Financial raised Bausch Health Cos to a “hold” rating in a report on Monday, December 15th. Finally, Wall Street Zen upgraded Bausch Health Cos from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Six research analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, Bausch Health Cos has a consensus rating of “Hold” and an average price target of $8.50.

Bausch Health Cos Company Profile

Bausch Health Cos Inc, formerly known as Valeant Pharmaceuticals International, is a global specialty pharmaceutical company headquartered in Laval, Quebec, Canada. The company operates through two primary segments: Ophthalmology, led by its Bausch + Lomb franchise, and Diversified Brands, which encompasses prescription dermatology, gastrointestinal, neurology and branded pharmaceutical products. Bausch Health develops, manufactures and markets a range of therapeutic and over-the-counter offerings designed to address conditions such as cataracts, dry eye, glaucoma, acne, rosacea, migraine and gastrointestinal disorders.

The Ophthalmology segment under the Bausch + Lomb name provides products for eye health, including prescription drops, contact lens care solutions, intraocular lenses, surgical instruments and diagnostic devices.